Hungta Chen

4.3k total citations · 1 hit paper
106 papers, 2.1k citations indexed

About

Hungta Chen is a scholar working on Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Hungta Chen has authored 106 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Endocrinology, Diabetes and Metabolism, 39 papers in Pulmonary and Respiratory Medicine and 27 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Hungta Chen's work include Diabetes Treatment and Management (41 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (38 papers) and Diabetes Management and Research (20 papers). Hungta Chen is often cited by papers focused on Diabetes Treatment and Management (41 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (38 papers) and Diabetes Management and Research (20 papers). Hungta Chen collaborates with scholars based in United States, United Kingdom and Sweden. Hungta Chen's co-authors include Donald Banerji, Peter D’Andrea, Vijay Alagappan, Jadwiga A. Wedzicha, Eric Bateman, Christie Arrasate, Joachim H. Ficker, Marc Decramer, Dennis E. Niewoehner and Thomas Sandström and has published in prestigious journals such as Journal of the American College of Cardiology, Diabetes Care and Diabetes.

In The Last Decade

Hungta Chen

100 papers receiving 2.1k citations

Hit Papers

Analysis of chronic obstructive pulmonary disease exacerb... 2013 2026 2017 2021 2013 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study
    2013 402 citations Jadwiga A. Wedzicha, Marc Decramer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hungta Chen United States 21 1.1k 896 714 280 227 106 2.1k
Dahlia Garza United States 17 1.4k 1.2× 321 0.4× 416 0.6× 235 0.8× 386 1.7× 41 2.7k
Mary Rose Stang Canada 14 556 0.5× 234 0.3× 255 0.4× 175 0.6× 183 0.8× 16 1.5k
Philip J. Klemmer United States 19 534 0.5× 204 0.2× 636 0.9× 292 1.0× 284 1.3× 38 1.9k
Gerjan Navis Netherlands 26 242 0.2× 350 0.4× 586 0.8× 315 1.1× 303 1.3× 79 2.5k
Carlo Garofalo Italy 25 354 0.3× 269 0.3× 415 0.6× 182 0.7× 341 1.5× 87 2.1k
Rigas Kalaitzidis Greece 24 215 0.2× 204 0.2× 407 0.6× 238 0.8× 236 1.0× 99 1.7k
Michel M. Joosten Netherlands 23 278 0.2× 192 0.2× 248 0.3× 135 0.5× 329 1.4× 40 1.7k
Chau Thach United States 13 1.0k 0.9× 794 0.9× 256 0.4× 54 0.2× 294 1.3× 26 1.7k
Li Fan China 22 275 0.2× 167 0.2× 297 0.4× 176 0.6× 231 1.0× 120 2.0k
Séverine Bompoint Australia 8 187 0.2× 124 0.1× 670 0.9× 214 0.8× 282 1.2× 13 1.3k

Countries citing papers authored by Hungta Chen

Since Specialization
Citations

This map shows the geographic impact of Hungta Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hungta Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hungta Chen more than expected).

Fields of papers citing papers by Hungta Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hungta Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hungta Chen. The network helps show where Hungta Chen may publish in the future.

Co-authorship network of co-authors of Hungta Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Hungta Chen. A scholar is included among the top collaborators of Hungta Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hungta Chen. Hungta Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pecoits‐Filho, Roberto, Eiichiro Kanda, Naoki Kashihara, et al.. (2025). Characteristics and cardio-renal outcomes in patients with CKD receiving guideline-directed medical therapy: insights from DISCOVER CKD. Nephrology Dialysis Transplantation. 41(3). 500–510.
2.
Heerspink, Hiddo J.L., Stephen Nolan, Juan Jesús Carrero, et al.. (2024). Clinical Outcomes in Patients with CKD and Rapid or Non-rapid eGFR Decline: A Report from the DISCOVER CKD Retrospective Cohort. Advances in Therapy. 41(8). 3264–3277. 5 indexed citations
3.
Alikhan, Raza, May Nour, Masahiro Yasaka, et al.. (2024). Design and rationale for REVERXaL: A real-world study of patients with factor Xa inhibitor–associated major bleeds. Thrombosis Research. 240. 109046–109046. 1 indexed citations
4.
Bongaerts, Brenda, Oliver Kuß, Fabrice Bonnet, et al.. (2023). HbA1c trajectories over 3 years in people with type 2 diabetes starting second‐line glucose‐lowering therapy: The prospective global DISCOVER study. Diabetes Obesity and Metabolism. 25(7). 1890–1899. 2 indexed citations
5.
Escobar, Carlos, Beatriz Palacios, Victoria González, et al.. (2023). Burden of Illness beyond Mortality and Heart Failure Hospitalizations in Patients Newly Diagnosed with Heart Failure in Spain According to Ejection Fraction. Journal of Clinical Medicine. 12(6). 2410–2410. 4 indexed citations
6.
Danysh, Heather E., Catherine B. Johannes, Daniel C. Beachler, et al.. (2022). Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Safety. 46(2). 175–193. 2 indexed citations
7.
Johannes, Catherine B., Daniel C. Beachler, J. Bradley Layton, et al.. (2022). Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Safety. 46(2). 157–174. 5 indexed citations
8.
Wittbrodt, Eric, Salvatore Barone, Matthew Arnold, et al.. (2021). REVEAL-CKD: Prevalence of Undiagnosed Early CKD in France and Japan. Journal of the American Society of Nephrology. 32(10S). 715–716. 1 indexed citations
9.
Khunti, Kamlesh, B Charbonnel, Hungta Chen, et al.. (2021). Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study. Diabetes Obesity and Metabolism. 23(8). 1956–1960. 13 indexed citations
10.
Patel, Krishna, Marília Brito Gomes, B Charbonnel, et al.. (2020). Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study. Diabetes Obesity and Metabolism. 23(1). 39–48. 7 indexed citations
11.
Khunti, Kamlesh, Marília Brito Gomes, Mikhail Kosiborod, et al.. (2020). Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme. BMJ Open. 10(8). e034613–e034613. 7 indexed citations
12.
Wang, Jun‐Sing, Hungta Chen, Fengming Tang, & Wayne Huey‐Herng Sheu. (2020). Associations of fear of hypoglycemia with second‐line use of insulin secretagogues or insulin and subsequent glycemic control in patients with type 2 diabetes: An analysis using data from the DISCOVER study. International Journal of Clinical Practice. 74(6). e13485–e13485. 5 indexed citations
13.
Dahl, Ronald, Dalal Jadayel, Vijay Alagappan, Hungta Chen, & Donald Banerji. (2014). Efficacy and Safety of Once-Daily QVA149 Compared With the Free Combination of Its Monocomponents: The BEACON Study. CHEST Journal. 145(3). 407A–407A. 2 indexed citations
14.
Welte, Tobias, Claus Vogelmeier, Ronald Dahl, et al.. (2013). Once-daily QVA149 has a good safety profile in patients with COPD. European Respiratory Journal. 42(Suppl 57). P757–P757. 6 indexed citations
15.
Decramer, Marc, Jadwiga A. Wedzicha, Joachim H. Ficker, et al.. (2013). Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study. European Respiratory Journal. 42(Suppl 57). P756–P756. 1 indexed citations
16.
Ficker, Joachim H., Jadwiga A. Wedzicha, Marc Decramer, et al.. (2013). QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study. European Respiratory Journal. 42(Suppl 57). 182–182. 1 indexed citations
17.
Mahler, Donald A., Tracy White, Vijay Alagappan, et al.. (2013). Development and validation of an innovative self-administered computerized (SAC) version of baseline/transition dyspnea index (BDI/TDI) for evaluating breathlessness in patients with COPD: The BLAZE study. European Respiratory Journal. 42(Suppl 57). P718–P718. 1 indexed citations
18.
Vogelmeier, C. Franz, Ronald Dahl, Anthony D’Urzo, et al.. (2013). Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes. European Respiratory Journal. 42(Suppl 57). P695–P695. 1 indexed citations
19.
Banerji, Donald, Angel FowlerTaylor, Pearl Kho, Hungta Chen, & Vijay Alagappan. (2013). Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis. European Respiratory Journal. 42(Suppl 57). P755–P755. 1 indexed citations
20.
Dahl, Ronald, Nicola Gallagher, Yulia Green, et al.. (2013). QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD. European Respiratory Journal. 42(Suppl 57). P3385–P3385. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dahlia Garza Breakdown of academic impact, for papers by Mary Rose Stang Breakdown of academic impact, for papers by Philip J. Klemmer Breakdown of academic impact, for papers by Gerjan Navis Breakdown of academic impact, for papers by Carlo Garofalo Breakdown of academic impact, for papers by Rigas Kalaitzidis Breakdown of academic impact, for papers by Michel M. Joosten Breakdown of academic impact, for papers by Chau Thach Breakdown of academic impact, for papers by Li Fan Breakdown of academic impact, for papers by Séverine Bompoint
Rankless by CCL
2026